

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Covenant Medical Center, Inc. 2. 1447 N. Harrison Saginaw, MI 48602	In accordance with letter dated January 16, 2008 , 3. License number 21-01492-02 is amended in its entirety to read as follows: 4. Expiration date December 31, 2014 5. Docket No. 030-02012 Reference No.
--	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed sources (Implant Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. I-125SL or I-125SH and IsoAid L.L.C., Model IAI-125A)	D. 1.15 curies
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged Kits	E. As needed

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. In vitro studies.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

21-01492-02

Docket or Reference Number

030-02012

Amendment No. 51

CONDITIONS

10. A. Licensed material, excluding 6.D., may be used at the licensee's facilities located at 700 Cooper Avenue, Saginaw, Michigan.
- B. Licensed material, excluding iodine-131 for thyroid carcinoma therapies may be used at the licensee's facilities located at 5400 Mackinaw Road, Saginaw Michigan.
11. The Radiation Safety Officer for this license is Mark Robert Ludka, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical uses:

Authorized UserMaterial and Use

Joseph E. Talbot, M.D.	10 CFR 35.100, 35.200 and 35.300.
Scott E. Cheney, M.D.	10 CFR 35.100 and 35.200.
Sanjay J. Talati, M.D.	10 CFR 35.100 and 35.200.
George F. Ascherl, M.D.	10 CFR 35.100, 35.200 and 35.300.
Harvey Yee, M.D.	10 CFR 35.100, 35.200 and 35.300.
C.E. Mueller, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Robert B. Saltzman, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Mark Robert Ludka, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Kristin M. Nelsen, M.D.	10 CFR 35.100, 35.200, and 31.11.
Rajnikant H. Mehta, M.D.	10 CFR 35.400.
Rajesh P. Kotecha, M.D.	10 CFR 35.400.
Paul G. Kocheril, M.D.	10 CFR 35.400.
James F. Littles, M.D.	10 CFR 35.400.
Sigrid E. Messana, D.O.	10 CFR 35.100, 35.200, and 31.11.
Chirdeep Bhutani, M.D.	10 CFR 35.100, 35.200 and 35.300.
Sambasiva Kottamasu, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

21-01492-02

Docket or Reference Number

030-02012

Amendment No. 51


Ramesh Vedula, M.D. 10 CFR 35.400.
Rita Ratani, M.D. 10 CFR 35.100 and 35.200.
Sultan Bhimani, M.D. 10 CFR 35.100, 35.200, and 31.11.
Shahzad Sadiq, M.D. 10 CFR 35.100, 35.200, and 35.300.

13. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Materials."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 24, 2004.
- B. Letters dated August 21, 2006, and December 4, 2006.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAR 12 2008

By



Toye L. Simmons
Materials Licensing Branch
Region III